Lucence Diagnostics, a genomic medicine company focused on inventing advanced cancer diagnostics, and Mascots Medical and Laboratory Centre, a healthcare service provider in Myanmar, announced today a partnership to distribute Lucence’s blood tests for cancer detection and treatment in Myanmar.
Lucence develops blood tests that diagnose cancer more quickly, accurately and cost-effectively with a single draw of blood. Through this collaboration, Mascots will market Lucence’s range of blood tests for cancer screening and treatment selection in Myanmar.
The tests are based on Lucence’s patented liquid biopsy technology, which detects circulating tumor DNA shed by the tumor into the bloodstream to identify the cancer-driving mutations. This allows doctors to select cancer treatment that is tailored to the unique genetic mutations in each patient’s cancer. Lucence’s liquid biopsy tests provide a non-invasive way to diagnose cancer compared to conventional tissue biopsy, which requires surgical removal of tissue from the body. The tests target breast, colon, lung and pancreatic cancers, among others.
Lucence also has a blood test for the early detection of nasopharyngeal cancer before symptoms show. The test detects a DNA fragment of the Epstein-Barr virus called BamHI-W, which is found in almost all patients with this cancer. Nasopharyngeal cancer is common in Southeast Asia and Southern China. Additionally, Lucence’s blood tests can check whether a person is predisposed to cancer by detecting genes commonly associated with increased risk of cancer.
Mascots Medical and Laboratory Centre provides a range of medical services including specialist consultation, health screening, diagnostics service, laboratory service, vaccination service as well as medical and laboratory referral services to Singapore hospitals. With this partnership, Lucence’s cancer blood tests will now be made available to all its customers in Myanmar.
“Myanmar is facing a cancer epidemic with death rates from cancer rising every year. There is a need for better ways to detect and treat cancer in Myanmar. Through this partnership with Lucence, we can provide simple blood tests to help our people detect cancer as early as possible, understand their risk of cancer, and provide them with a better choice of cancer treatment,’’ said Dr. Thynn Myo Myo Aye, Director, Mascots Medical and Laboratory Centre.
“Lucence is delighted to collaborate with Mascots to launch our liquid biopsy tests in Myanmar. Our blood tests enable precision medicine by tailoring cancer treatments to individual patients. This will lead to more effective treatment and improve cancer survival rate. Together with Mascots, we hope to drive better cancer care in Myanmar,” said Dr. Min-Han Tan, Founder and CEO, Lucence Diagnostics.
 World Health Organization
 2012 Cancer Preview Report by the Asia Pacific Journal
For more information, please contact:
About Lucence Diagnostics
Lucence Diagnostics is a genomic medicine company focused on personalizing cancer care. Headquartered in Singapore with offices in Hong Kong and San Francisco, Lucence invents genomic tests that enable earlier cancer diagnosis and better treatment selections. Lucence’s tests target the most common cancers in Asia using proprietary technology and clinical analytics. Its key operations are supported by an ISO 15189 accredited molecular diagnostics laboratory and a cancer genetics clinic. For more information, please visit www.lucencedx.com.
Mascots Healthcare was established in 1998 to deliver healthcare services to physicians and patients in Myanmar. Mascots started its laboratory referral service, in 2000 and its medical referral services to two hospitals in Singapore in 2005: National University Hospital and Tan Tock Seng Hospital. This medical referral service was expanded to include Mount Alvernia Hospital in 2013, and Farrer Park Hospital in 2017. To provide better healthcare services in Myanmar, the Mascots Medical and Laboratory Centre was set-up in 2017 to provide specialist consultations, health screening, vaccination, diagnostic and laboratory services.